The Ledger

Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.

clear all ✕

why aren't all 2 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable

Insight
Ari Lipman: Low-value commodities present severe market entry hurdles for biotech
“If you're making something that's super low value it's pretty hard to break into a new market.”
Ari Lipman Jan 18, 2022 ▶ 7:58 Microbes, meat and materials: biotech meets climatetech
Insight
Lipman: Synbio startups should prioritize niche, high-value markets
“You know, you always want to try to own a larger portion of a small market than try to own a small portion of a large market, at least at the outset. So I think, and that has been the tradition across the biotech industry and across synthetic biology is go for…”
Ari Lipman Jan 18, 2022 ▶ 30:24 Microbes, meat and materials: biotech meets climatetech
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 200 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.